PMID- 25744707
OWN - NLM
STAT- MEDLINE
DCOM- 20170307
LR  - 20171213
IS  - 1724-6075 (Electronic)
IS  - 0391-5603 (Linking)
VI  - 82
IP  - 2
DP  - 2015 Apr-Jun
TI  - Clinical efficacy and safety of Vitaros(c)/Virirec(c) (Alprostadil cream) for the 
      treatment of erectile dysfunction.
PG  - 84-92
LID - 10.5301/uro.5000116 [doi]
AB  - Erectile dysfunction (ED) is a very common disorder with a deep impact on 
      patients and their partners. Several options are now available for treating ED; 
      oral pharmacotherapy with phosphodiesterase-5 (PDE5) inhibitors currently 
      represents the first-line option for many ED patients. Vitaros(c)/Virirec(c) is new 
      topical, non-invasive treatment for ED that offers the combination of an active 
      drug (alprostadil, a synthetic PGE1) with a skin enhancer that improves its local 
      absorption directly at the site of action. Vitaros(c)/Virirec(c) has a favorable 
      pharmacodynamic profile and is poorly absorbed in systemic circulation. This 
      makes it suitable in any circumstances and results in a reduced risk of adverse 
      events (AEs), being systemic AEs reported in only 3% of the treated population. 
      Its clinical efficacy has been demonstrated in both phase II and III trials, 
      showing a global efficacy up to 83% with the 300 mug dose in patients with severe 
      ED significantly better than placebo. Its fast onset of action together with its 
      favorable toxicity profile and lack of interactions with other drugs makes 
      Vitaros(c)/Virirec(c) a first-line therapeutic option for patients with ED, 
      particularly for individuals who are reluctant to take systemic treatments or 
      with AEs. It may also have an important role in patients not responding to PDE5 
      inhibitors, particularly those with ED after radical prostatectomy.
FAU - Moncada, Ignacio
AU  - Moncada I
AD  - 1 Hospital La Zarzuela c/Pleyades, Madrid - Spain.
FAU - Cuzin, Beatrice
AU  - Cuzin B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150303
PL  - United States
TA  - Urologia
JT  - Urologia
JID - 0417372
RN  - 0 (Vasodilator Agents)
RN  - F5TD010360 (Alprostadil)
SB  - IM
MH  - Alprostadil/*administration & dosage
MH  - Erectile Dysfunction/*drug therapy/etiology
MH  - Humans
MH  - Male
MH  - Skin Cream/administration & dosage
MH  - Treatment Outcome
MH  - Vasodilator Agents/*administration & dosage
EDAT- 2015/03/07 06:00
MHDA- 2017/03/08 06:00
CRDT- 2015/03/07 06:00
PHST- 2015/02/11 00:00 [accepted]
PHST- 2015/03/07 06:00 [entrez]
PHST- 2015/03/07 06:00 [pubmed]
PHST- 2017/03/08 06:00 [medline]
AID - C1388E7A-1598-4CF0-9E80-303592D81303 [pii]
AID - 10.5301/uro.5000116 [doi]
PST - ppublish
SO  - Urologia. 2015 Apr-Jun;82(2):84-92. doi: 10.5301/uro.5000116. Epub 2015 Mar 3.